A 2026 national survey of Dutch emergency physicians found wide variation in first-line medication choices for extreme agitation: without intravenous access, 34.7% preferred midazolam, 23.1% preferred droperidol, 14.3% preferred droperidol plus midazolam, and 10.4% preferred esketamine.1 The result is a practice map, not an outcome trial, but it shows how emergency clinicians are balancing rapid …
A 2026 real-world study involving 1,174 children with epilepsy proposed a levetiracetam therapeutic drug monitoring range of 2.82-24.37 mcg/mL, much lower than commonly cited adult-style ranges, but the same data also warned against treating a drug level as a stand-alone seizure-control predictor. Research Highlights Lower pediatric range: Sun et al. proposed an observational levetiracetam range …
A 2026 individual participant data meta-analysis of 1,721 dementia trial participants linked risperidone to cerebrovascular adverse events, HR 4.11 (95% CI 1.77 to 9.51), and major cardiovascular adverse events, HR 2.00 (95% CI 1.23 to 3.26).1 The timing signal is the practical warning: median first cerebrovascular event appeared at 4.3 weeks, and median first major …
Zuranolone, a novel antidepressant, shows promise in treating depression, as evidenced by a recent meta-analysis. A new study investigated zuranolone’s efficacy and safety, focusing on short-term rapid antidepressant effects. Highlights: Zuranolone Effectiveness: Demonstrated significant improvement in depression severity scores compared to placebo, with notable effects by day 15. Treatment-Emergent Adverse Events (TEAEs): Increased incidence in …